Dr Reddy's announces settlement of Exelon (rivastigmine tartrate ) ANDA litigation with Novartis

By Our Corporate Bureau | 21 Jan 2008

1

Dr Reddy's Laboratories Ltd today announced that the company has entered into a settlement agreement with Novartis Pharma AG, which involves a stipulation of dismissal of the lawsuits in the United States relating to the abbreviated new drug applications filed by Dr Reddy's for a generic version of rivastigmine tartrate capsules sold under the trade-name Exelon.

Under the terms of the agreement, Dr Reddy's will not launch its generic Rivastigmine Tartrate capsules until some time before the expiry of the Orange Book patents claiming Rivastigmine. The exact date of launch and other terms of this agreement are confidential.

In October 2007, the company received the final approval from US FDA on its ANDA for Rivastigmine capsules.

Rivastigmine tartrate capsules is the generic version of the Novartis' product Exelon indicated for the treatment of mild-to-moderate Alzheimer's disease dementia. As per the IMS June 2007 moving annual total, the annual sales of this product in the US were $199 million.

Business History Videos

History of hovercraft Part 3...

Today I shall talk a bit more about the military plans for ...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of hovercraft Part 2...

In this episode of our history of hovercraft, we shall exam...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Hovercraft Part 1...

If you’ve been a James Bond movie fan, you may recall seein...

By Kiron Kasbekar | Presenter: Kiron Kasbekar

History of Trams in India | ...

The video I am presenting to you is based on a script writt...

By Aniket Gupta | Presenter: Sheetal Gaikwad

view more